FDA To Accept Wright’s PMA Amendment For Augment Bone Graft
This article was originally published in The Gray Sheet
The agency has agreed to accept Wright Medical’s PMA amendment for its embattled Augment bone graft, saving the firm from going to a dispute resolution panel this spring.
You may also be interested in...
Financial earnings reports from Smith & Nephew, Wright Medical, Zimmer, Stryker and Orthofix.
The all-stock transaction valued at around $3.3 billion will create a device and biologics company with a comprehensive focus on orthopedic extremities surgery. The firms expect cost synergies of $40 to $45 million.
With more data submitted to CDRH, FzioMed and the device center have agreed to postpone a planned June 10 dispute-resolution panel meeting on the firm’s previously rejected PMA for the Oxiplex spine surgery gel.